Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

Amgen still has no magic pill to solve its zero-growth problem

  • Adam Feuerstein
  • Damian Garde

By Adam Feuerstein and Damian Garde April 25, 2018

Reprints
Amgen HQ
Mark J. Terrill/AP

Flat is the new killing it.

Amgen’s (AMGN) first-quarter earnings beat Wall Street’s expectations on Tuesday night, and so the market was sated. But is anyone worried about the company’s growth?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Study finds same small rise in breast cancer risk…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Vote now in STAT Madness 2023
Vote now in STAT Madness 2023
Take our quiz: Can you out-science a high schooler?
Take our quiz: Can you out-science a high schooler?
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug

Recommended Stories